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DEPOORTERE, H., D. FRANCON, E. L. J. M. VAN LUIJTELAAR, W. H. I. M. DRINKENBURG AND 
A. M. L. COENEN. Differential effects of midazolam and zolpidem on sleep-wake states and epileptic activity in WAG/ 
Rij rats. PHARMACOL BIOCHEM BEHAV S(4) 571-576, 1995. -Hypnotic drugs are known to possess antiepileptic 
activity. Therefore, the effects of the benzodiazepine hypnotic midazolam (10 mg/kg) and the novel imidazopyridine hypnotic 
zolpidem (10 mg/kg) on sleep-wake states and on the number of spike-wave discharges were evaluated in WAG/Rij rats. Rats 
of this strain are considered to be a model for generalized absence pilepsy. Animals were implanted with chronic monopolar 
EEG electrodes and, after recovery from surgery, the EEG was recorded for 6 h during the dark period on 3 consecutive days. 
Sleep recordings were analyzed using Hjorth’s parameters and number and duration of spike-wave discharges were visually 
determined. It was found that both drugs facilitated nonREM sleep at the cost of wakefulness. Both hypnotics also reduced 
the number and duration of spike-wave discharges. The initial decrease after midazolam, however, was followed by a rebound 
reflecting a poorer quality of vigilance expressed as an increase in spike-wave discharges. The strong antiabsence activity of 
zolpidem mimics that of midazolam and is well correlated with their equipotent hypnotic action and anticonvulsant effect in 
the isoniazid test. 
Sleep-wake states Spike-wave discharges Absence epilepsy Midazolam Zolpidem Hypnotics 
WAG/Rij strain Rats Rebound effects 
FOR THE last 2 decades benzodiazepines have been the anxio- 
lytics and hypnotics of first choice due to their efficacy, their 
relatively mild side effects, and their safety. A standing prob- 
lem is that they also induce daytime drowsiness, which is often 
accompanied by muscular relaxation (6). Moreover, it has be- 
come increasingly clear that benzodiazepines affect cognitive 
functioning and psychomotor performance (16,20,25). Next 
to all these actions, benzodiazepines how broad spectrum 
antiepileptic properties: they reliably reduce various types of 
convulsions and counteract spike-wave discharges. 
Until recently, it was generally assumed that these different 
effects of benzodiazepines are indissolubly linked. Nowadays, 
research efforts are aimed at separating the different actions 
of the benzodiazepines, and new drugs are currently being 
developed that do not possess all the effects of the benzodiaze- 
pines. Investigations of partial agonists at the benzodiazepine 
(w) receptors suggest hat it is, indeed, possible to separate 
these effects. Concrete examples were presented by Coenen 
and van Luijtelaar (3). who demonstrated that the hypnotic 
and antiepileptic action of ZK 91296 were discriminable. Ste- 
phens et al. (24) and Coenen et al. (5) also showed that the 
anxiolytic and hypnotic actions of abecamil were distinguish- 
able. 
The novel hypnotic, zolpidem, an imidazopyridine deriva- 
tive, shares many of the pharmacological actions characteris- 
tic of benzodiazepines. There are, however, differences such 
as the weaker myorelaxant effects of zolpidem (1,lO). De- 
poortere et al. (10) investigated the anticonvulsant profile 
of zolpidem in pentylenetetrazol-induced convulsions and in 
the electroshock model. They demonstrated a considerable 
weaker anticonvulsant activity for zolpidem than for the ben- 
zodiazepines midazolam, triazolam, and flunitrazepam in 
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these models. However both categories of drugs, ligands of 
the GABA-benzodiazepine receptor complex, have equipotent 
hypnotic activity (1 l), as well as anticonvulsant effects in the 
isoniazid convulsant model (30). Based on the latter findings, 
it is likely that zolpidem, like the benzodiazepines, inhibits 
spike-wave discharges. 
The purpose of the present study was to evaluate the effects 
on sleep-wake states and on the amount of epileptic activity 
of the classical benzodiazepine hypnotic midazolam and the 
nonbenzodiazepine hypnotic zolpidem. This was done in 
WAG/Rij rats, which show spontaneously occurring spike- 
wave discharges in the EEG and are considered as an adequate 
model for human absence epilepsy (4,27). 
METHOD 
Experiments were performed on 10 male WAG/Rij rats, 
weighing between 320 and 400 g. They were maintained under 
identical environmental conditions, under a 12 L : 12 D cycle 
and a constant temperature of 21 OC. Rats were anesthetized 
with an intraperitoneal injection of 50 mg/kg sodium pento- 
barbital and implanted with three small electrode screws on 
each hemisphere. The first electrode was screwed into the skull 
above the sensorimotor cortex (1.5 mm lateral to the median 
suture and 1.5 mm behind the fronto-parietal suture), the sec- 
ond one into the skull above the visual cortex (1.5 mm lateral 
to the median suture and 1.5 mm in front of the parieto- 
occipital suture), and the third one above the cerebellum. The 
latter served as a reference electrode. All electrodes were 
attached to a seven-lead Winchester connector fixed with den- 
tal cement to the cranium. Three weeks of postoperative re- 
covery were allowed. During this period, half of the rats were 
habituated to a reversed light : dark cycle, whereas the other 
half kept the regular cycle with lights on between 0700 and 
1900 h. There was no difference between the two groups of 
five rats: they had the same ages and weights (360 k 20 g). 
Four days before the experiment, the animals were placed in 
Plexiglas cylinders with free access to food and water (habitu- 
ation period to experimental conditions). Each rat was in- 
jected twice at intervals of at least 3 weeks and recorded from 
1100-1700 h. Experiments with 10 mg/kg PO of zolpidem or 
midazolam were conducted during 3 consecutive days in five 
rats habituated to a reversed light : dark cycle, as this is the 
condition required to observe a hypnotic effect of midazolam 
(9). The first day being a first control day (vehicle, distilled 
water), followed by a drug day (either zolpidem or midazo- 
lam), and again followed by a second control day (vehicle). 
The dose of 10 mg/kg PO was chosen for both zolpidem and 
midazolam because of their equal potencies on sleep-wake 
states in normal rats (9-l 1). The other five rats were recorded 
during the light period after treatment with vehicle (control 
day) on two occasions at interval of 3 weeks. 
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Three sleep-wake states were differentiated, as follows 
(7,9): wakefulness (W; characterized by low voltage fast EEG 
activity), non-REM sleep (drowsiness and slow-wave sleep 
characterized by larger EEG activity and by high amplitude 
slow waves with bursts of sleep spindles), and paradoxical 
sleep or REM sleep (characterized by periods of hypersynchro- 
nous theta rhythm in the visual area and low-voltage EEG 
activity in the sensorimotor area). 
The EEG was automatically analyzed by a computerized 
system that discriminates between these states. The system, 
which uses Hjorth’s descriptors, has been described in detail, 
validated, and extensively used (815). The performance of the 
system was regularly checked against visual scoring. Baseline 
parameters for the light and dark period were determined, 
while drug effects were only evaluated in the dark period, the 
most sensitive part of the light : dark cycle to evaluate hyp- 
notic effects and antiabsence ffect on spike-wave discharges 
(9,28,29). Spike-wave discharges were counted based on crite- 
ria published elsewhere, whereby the number and total dura- 
tion of the spike-wave discharges per hour were determined 
(27). Within-group comparisons were made with Student’s i- 
test for paired observations. 
RESULTS 
Sleep-wakefulness characteristics for the baseline light and 
dark period are presented in Table 1. This table shows that the 
rats predominantly slept during the light period (74% of total 
time) and that the percentages of non-REM sleep and REM 
sleep, the number of REM periods, and the mean length of 
periods of REM sleep were greater in the light than in the dark 
period. The rats had more spike-wave discharges during the 
dark period (mean and standard error: 197 f 21) than during 
the light period (85 f 8). 
Zolpidem reduced wakefulness and increased non-REM 
sleep during the first 2 h following administration. No signifi- 
cant effects were seen on REM sleep. The data are shown 
in Fig. la. One day later, non-REM sleep was reduced and 
wakefulness was increased for the first hour of recording. 
Zolpidem decreased the number and total duration of 
spike-wave discharges (Fig. 2a). These effects were present 
during the first 3 h after administration. The number and 
duration of the spike-wave discharges on the postdrug day did 
not differ from predrug values, except that the duration was 
still reduced during the first hour on the postdrug day. 
Midazolam increased non-REM sleep and reduced wake- 
fulness. The results are shown in Fig. lb. Midazolam reduced 
the number and duration of spike-wave discharges during the 
first 3 h following drug administration (Fig. 2b). This initial 
decrease was followed by a significant increase in number and 
total duration at the fifth hour of the experimental day. The 
total duration of the spike-wave discharges was still enhanced 
TABLE 1 
SLEEP-WAKEFULNESS PARAMETERS OF WACi/Rij RATS RECORDED DURING THE LIGHT AND 
THE DARK PERIOD (MEAN OF TWO EXPERIMENTS ON FIVE RATS) 
Recordings During W% non-REM% REM% nREM =EM s nSWD dSWD s 
Light 24.2 + 1.5 65.4 + 1.1 10.4 f 1.3 19 f 1 116 zt 7 85+ 8 440+ 82 
Dark 59.2 + 2.5 38.6 f 2.5 2.2 + 0.8 7+2 89 f 3 197 * 21 1534 f 159 
The results (f SEM) are expressed as percentages for _wakefuIness (W), nonREM sleep, REM sleep, number of REM 
periods (nREM), mean duration of REM periods in s (xREM), number of spike-wave discharges (nSWD), and total 
duration of spike-wave discharges in seconds (dSWD) in a 6-h recording period during the first control day. 
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FIG. 1. (a) Effects of zolpidem (10 mg/kg PO) on sleep-wake states in WAG/Rij rats recorded during the dark period (n = 5). *p I 0.05; l *p 
s 0.01 vs. control values. (5) Effects of midazolam (10 mg/kg PO) on sleep-wake states in WAG/Rij rats recorded during the dark period (n = 
5). l p 5 0.05; **p 5 0.01 vs. control values. 
on the sixth hour after administration and during the first 
hour on the postdrug day; this was followed by a steady de- 
cline to predrug levels. 
An overview of the main outcomes is presented in Table 
2. Both drugs facilitated non-REM sleep at the expense of 
wakefulness and reduced the number and duration of spike- 
wave discharges with a similar efficacy. On the second control 
day, the two drugs differed in that zolpidem decreased non- 
-REM sleep and the number of spike-wave discharges while 
midazolam increased spike-wave activity. 
DISCUSSION 
The sleep-wakefulness profile of WACVRij rats differs 
from that commonly seen in other laboratory rats. The low 
percentage REM sleep for the dark period (2%) seems to be 
smaller than commonly reported (5%) (2,9,18,26). Also, the 
duration of the REM periods seems to be shorter than found 
earlier for outbreds in the same laboratory (7). Thus, it seems 
that WAG/Rij rats spend less time in REM sleep than other 
rats, and this was directly evaluated by Gandolfo et al. (13) 
who reported that WAG/Rij rats have less REM sleep periods 
per hour, with a lower percentage of REM sleep, and that 
these rats seemed to have difficulties entering into REM sleep. 
Despite differences in genotype between outbred and 
WAG/Rij rats, it seems that both midazolam and zolpidem 
reliably induce nonREM sleep at the cost of wakefulness (Ta- 
ble 2). The hypnotic effects of zolpidem were earlier described 
by Depoortere et al. (IO,1 l), and the present results suggest 
that the hypnotic effects of both drugs are independent of the 
rat’s genotype. However, the two drugs differ in their effects 
on rebound spike-wave discharges and on sleep 24 h following 
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EFFECTS OF MIDAZOLAM AND ZOLPIDEM IN WAG/Rij RATS 
TABLE 2 
EFFECTS OF ZOLPIDEM AND MIDAZOLAM ON THE SLEEP-WAKEFULNESS PARAMETERS OF WAG/Rij RATS RECORDED 
DURING THE DARK PERIOD (n = 5 PER EXPERIMENT; RECORDINGS FROM 1100-1700 h) 
575 
Control 
Zolpidem 
10 mg/kg PO A Second control A Control 
Midazohm 
10 mg/kg PO A Second control A 
W (set) 12600 * 501 11591 k 525 -8 13730 f 812 +9 12982 * 559 11679 f 219 -10 12459*646 -4 
non-REM (set) 8491 f 444 9766 + 504 + 15* 7450 f 689 - 12* 8162 f 521 9450 * 186 +16* 8619 rt 695 +6 
nSWD 208 + 19 126 f 20 -39* 158 + 16 -24* 186 + 23 108 * 7 -42* 256 f 50 +38 
dSWD (sec.) 1805 t 192 1261 f 285 - 30* 1880 + 269 +4 1296 f 127 881 f 92 -32 2162 f 20 +67* 
* p s 0.05 Student’s f-test for paired values. For legends, see Table 1. 
their administration. Zolpidem induced a decrease of non- 
REM sleep during waking (dark) period, which was not found 
for midazolam. Zolpidem does not appear to cause rebound 
insomnia or to have residual sedative effects in the morning in 
humans (19), although these phenomena are well known with 
benzodiazepines (14,17,21). 
The decrease in the number and duration of spike-wave 
discharges after midazolam was expected considering the well- 
known antiepileptic action of benzodiazepines (22). However, 
the reduction in spike-wave discharges een with zolpidem was 
as marked as that of midazolam. It is known that the anticon- 
vulsant action of zolpidem in pentylenetetrazol-induced sei- 
zures or in electroshock convulsions is less than those of the 
benzodiazepines flunitrazepam and midazolam (10). Thus, 
zolpidem is 225 and 69 times less potent than flunitrazepam 
and midazolam, respectively, in pentylenetetrazol-induced 
convulsions, and 13 and 8 times less potent in electroshock 
convulsions. On the other hand, zolpidem is more active in 
convulsive models that involve impairment in GABAergic 
transmission, e.g., isoniazid-induced convulsions. It possesses 
the same or an even higher efficacy as compared to flunitra- 
zepam and midazolam, in this model (30). The present data 
shows that midazolam and zolpidem are equally effective in 
suppressing spike-wave discharges, and these effects seem to 
be correlated with their hypnotic and antiisoniazid potency. 
The decrease in the number of spike-wave discharges fol- 
lowing midazolam was followed by an increase in the number 
of spike-wave discharges. To our knowledge, rebound effects 
on spontaneous epileptic activity have not previously been 
reported. Only following abrupt cessation of chronic benzodi- 
azepine administration was an increase in susceptibility for 
epileptic seizures reported (23). The rebound effects seen only 
on spike-wave discharges but not on sleep after midazolam 
could reflect a poorer quality of vigilance, with an increase 
of quiet wakefulness-drowsiness periods, because spike-wave 
discharges preferentially occur during periods with a low level 
of vigilance (12). In contrast, zolpidem maintains an adequate 
level of vigilance after its hypnotic effect during the waking 
(dark) period without rebound of spike-wave discharges. 
In all, the present data show comparable hypnotic effects 
of zolpidem and midazolam in rats with a different genotype 
than commonly used. They further suggest an equal potency 
of these drugs to suppress pike-wave discharges in WAG/Rij 
rats. Finally, the data show a rebound effect on spike-wave 
activity for midazolam that could reflect a poorer quality of 
vigilance, but this warrants further investigation. 
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